Write your message
Volume 5, Issue 2 (Spring 2020)                   J Obstet Gynecol Cancer Res 2020, 5(2): 68-71 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Pooransari P, Shirazi M. Comparative Evaluation Between First and Second Trimester Aneuploidy Screening Tests with Amnio Synthesis Results. J Obstet Gynecol Cancer Res. 2020; 5 (2) :68-71
URL: http://jogcr.com/article-1-267-en.html
1- Assistant Professor, Shohada Hospital, Shahid Beheshti University of Medical Science (Sbmu), Tehran, Iran
2- Maternal Fetal and Neonatal Research Center, Tehran University of Medical Sciences, Yas Hospital, Tehran, Iran , Mahboobehshirazi4@gmail.com
Abstract:   (863 Views)
  Background & Objective: Screening tests for common aneuploidy, especially trisomies 21, 18, and 13, should be offered to pregnant people of all ages at first and second trimesters. Theses include combined tests (nuchal translucency (NT)+biochemical pregnancy-associated plasma protein-A (PAPP-A), free beta-human chorionic gonadotropin (β-hCG)) and quad test. If the tests are positive based on cut-off value of 1:250, diagnostic tests such as amniocentesis and chorionic villus sampling (CVS) are suggested. The current study aimed to comparatively evaluate the results of these screening tests and amniocentesis.
Materials & Methods: This practical-basic study was designed to evaluate the accuracy of first and second trimester screening tests with amniocentesis results. A total of 45 subjects were selected from the patients referred for abnormal screening tests toShohadaya-ye-Tajrish hospital in Tehran, Iran, during 2014-2015. The results of tests (combined or quad) were positive based on cut-off value of 1:250. Data was collected through a questionnaire containing such information as age, gravidity, previous aneuploidy births, placenta location, blood group, amniotic fluid color, type of sampling needle, and mode of needle entrance.
Results: The mean age of patients was 33.16 years. There was significant p-value between positive results of amniocentesis and age of the patients. Out of 45 amniocentesis tests, four had abnormal results (two in the first trimester (2/17) and two in the second trimester (2/24)). Also, three items were T21 and the forth was translocation between chromosome 11-22. We had one fetal loss due to amniocentesis procedure.
Conclusion: Diagnostic tests are suggested for better evaluation of abnormal results. These screening tests have false positive and negative results. We attempted to evaluate the real results with invasive tests. Further research is needed to investigate the accuracy of screening aneuploidy tests.
 
 
Full-Text [PDF 263 kb]   (193 Downloads) |   |   Full-Text (HTML)  (215 Views)  
Systematic Review: Original Research | Subject: Maternal Fetal Medicine
Received: 2020/07/13 | Accepted: 2020/07/26 | Published: 2020/10/28

References
1. Cunningham, L. B, SPONG, Dash, Hoffman, Casey, Sheffield, Williams obstetric. 24th ed. Vol.1. 2018, 419-455
2. Godino L, Pompilii E, D'anna F, Morselli-Labate AM, Nardi E, Seri M, Rizzo N, Pilu G, Turchetti D. Attitudes of women of advanced maternal age undergoing invasive prenatal diagnosis and the impact of genetic counselling. Eur J Hum Genet. 2016;24(3):331-7. [DOI:10.1038/ejhg.2015.116] [PMID] [PMCID]
3. Nicolaides KH. Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities. Am J Obstet Gynecol. 2004;191(1):45-67. [DOI:10.1016/j.ajog.2004.03.090] [PMID]
4. Gekas J, Langlois S, Ravitsky V, Audibert F, van den Berg DG, Haidar H, Rousseau F. Identification of trisomy 18, trisomy 13, and Down syndrome from maternal plasma. APP Clin Genet. 2014;7:127. [DOI:10.2147/TACG.S35602] [PMID] [PMCID]
5. Akolekar R, Beta J, Picciarelli G, Ogilvie C, D'Antonio F. Procedure‐related risk of miscarriage following amniocentesis and chorionic villus sampling: a systematic review and meta‐analysis. Ultrasound Obstet Gynecol. 2015;45(1):16-26. [DOI:10.1002/uog.14636] [PMID]
6. Kavoosi ES, Younessi S, Farhud DD. Screening of fetal chromosome aneuploidies in the first and second trimester of 125,170 Iranian pregnant women. Iran J Public Health. 2015;44(6):791.
7. Tara F, Lotfalizadeh M, Moeindarbari S. The effect of diagnostic amniocentesis and its complications on early spontaneous abortion. Electro Physic. 2016;8(8):2787. [DOI:10.19082/2787] [PMID] [PMCID]
8. Shirazi M, Sarmadi S, Niromanesh S, Rahimi Sharbaf F, Sahebdel B, Golshahi F, Asadi L, Rahmanzadeh M. Assessment of the Sensitivity and Specificity of Screening Tests Performed in the First and Second Trimester in the Pregnant Women. J Obstet Gynecol Cancer Res (JOGCR). 2019;4(1):12-5. [DOI:10.30699/jogcr.4.1.12]
9. Niromanesh S, Mousavi Darzikolaei N, Rahimi-Shaarbaf F, Shirazi M. Pregnancy outcome in amniocentesis and chorionic villous sampling: ten-year report. Tehran Uni Med J TUMS Pub. 2016;74(6):400-7.
10. Shirazi M, Azadi F, Shariat M, Niromanesh S, Shirazi M. Effectiveness of stress management training on stress reduction in pregnant women. Tehran University Medical Journal TUMS Publications. 2016;74(7):493-9.
11. Shirazi M, Mohseni M, Ghajarzadeh M. Complications, indications and results of two screening methods: amniocentesis and chorionic villus sampling. Aca J Surg. 2015;2(1-2):23-6.
12. Shirazi M, Rabiei M, Rahimi F, Niroomanesh S, Golshahi F, Yazdi ME. Does chorionic villus sampling increase the risk of preeclampsia or gestational hypertension?. Int J Prevent Med. 2019;10. [DOI:10.4103/ijpvm.IJPVM_83_16] [PMID] [PMCID]
13. Shirazi M, Pooransari P, Sharbaf FR, Niromanesh S, Sahebdel B, Shariat M, Pahlavan Z, Shirazi M, Ahmadian M. Correlation of maternal stress because of positive aneuploidy screening serum analytes and uterine arteries' doppler ultrasound index: a prospective cohort study. International journal of fertility & sterility. 2019;12(4):329.
14. Torkzaban M, Kalateh A, Rajabpoor Nikoo N, Shirazi M. Analysis of Ultrasonographic Misdiagnosis of Cephalothoracopagus Janiceps Conjoined Twins: A Case Report. J Obstet Gynecol Cancer Res. 2020;5(1):8-. [DOI:10.30699/jogcr.5.1.27]
15. Odibo AO, Stamilio DM, Nelson DB, Sehdev HM, Macones GA. A cost-effectiveness analysis of prenatal screening strategies for Down syndrome. Obstet Gynecol. 2005;106(3):562-8. [DOI:10.1097/01.AOG.0000174581.24338.6f] [PMID]
16. Merkatz IR, Nitowsky HM, Macri JN, Johnson WE. An association between low maternal serum α-fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol. 1984;148(7):886-94. [DOI:10.1016/0002-9378(84)90530-1]
17. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. The Lancet. 1998;352(9125):343-6. [DOI:10.1016/S0140-6736(97)11280-6]
18. Crossley JA, Aitken DA, Cameron AD, McBride E, Connor JM. Combined ultrasound and biochemical screening for Down's syndrome in the first trimester: a Scottish multicentre study. Int J Gynecol Obstet. 2002;109(6):667-76. [DOI:10.1111/j.1471-0528.2002.01394.x] [PMID]
19. Lewis G, Drife J, Botting B, Carson C, Cooper G, Hall M, et al. Why mothers die 1997-1999. The fifth report of the confidential enquiries into maternal deaths in the United Kingdom. London: RCOG Press, 2001.
20. Drife J, Lewis G. Why mothers die, 1997-1999: The Fifth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. London: Royal College of Obstetricians and Gynaecologists. 2001.
21. Marteau TM, Kidd J, Cook R, Johnston M, Michie S, Shaw RW, Slack J. Screening for Down's syndrome. Br Med J. 1988;297(6661):1469-1469. [DOI:10.1136/bmj.297.6661.1469-b] [PMID] [PMCID]
22. Marteau TM. Screening, ethics and the law. Br Med J. 1992 Dec 5;305(6866):1433-1434. [DOI:10.1136/bmj.305.6866.1433-e] [PMID] [PMCID]
23. Spencer K. Antenatal screening for Down's syndrome. BMJ. 1992;305(6856):769-771. [DOI:10.1136/bmj.305.6856.769] [PMID] [PMCID]
24. Marteau TM, Johnston M, Shaw RW, Slack J. Factors influencing the uptake of screening for open neural-tube defects and amniocentesis to test for Down's syndrome. Br J Obstet Gynaecol. 1989;96(6):739-741. [DOI:10.1111/j.1471-0528.1989.tb03295.x] [PMID]
25. Sheldon TA, Simpson J. Appraisal of a new scheme for prenatal screening for Down's syndrome. BMJ. 1991;302(6785):1133-1136. [DOI:10.1136/bmj.302.6785.1133] [PMID] [PMCID]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License Journal of Obstetrics, Gynecology and Cancer Research by Farname Inc is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Based on a work at http://jogcr.com/.

© 2022 CC BY-NC 4.0 | Journal of Obstetrics, Gynecology and Cancer Research (JOGCR)

Designed & Developed by : Yektaweb | Piblisher: Farname Inc.